Brief: Alkermes Receives FDA Fast Track Designation For Nemvaleukin Alfa In Combination With Pembrolizumab For Treatment Of Platinum-Resistant Ovarian Cancer
25/10/2021 12:09
Oct 25 (Reuters) - Alkermes Plc ALKS.O :
* ALKERMES RECEIVES FDA FAST TRACK DESIGNATION FOR
NEMVALEUKIN
ALFA IN COMBINATION WITH PEMBROLIZUMAB FOR THE TREATMENT OF
PLATINUM-RESISTANT OVARIAN CANCER
Source text for Eikon: ID:nPn8ZRsJma
Further company coverage: ALKS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alkermes
See all newsBrief: Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 2 At Sleep 2026
Brief: Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz
Brief: Alkermes Announces Effectiveness Of Mural Oncology Form 10 Registration Statement
Alkermes Plc reports results for the quarter ended in September - Earnings Summary
Brief: Alkermes Q3 Net Income USD 47.8 Million